New research from UCLA Health suggests that GLP-1 receptor agonists, commonly used for type 2 diabetes and obesity, may lower the risk of serious fractures in older adults, challenging concerns about their impact on bone health.
New research from UCLA Health suggests GLP-1 medicines, a class widely used to treat type 2 diabetes and obesity, may also be linked to a lower risk of serious fractures in older adults with diabetes. The study, published in JAMA Network Open, examined electronic health records for nearly 134,000 U.S. adults aged 50 to 90 and compared new users of GLP-1 receptor agonists with new users of DPP-4 inhibitors, another common diabetes drug class.
Researchers found that people who started GLP-1 treatment had a 21% lower risk of fragility fracture over three years than those who began DPP-4 therapy. The greatest differences were seen in fractures of the hip, femur and spine. Fragility fractures are usually caused by low-energy falls, such as falling from standing height, and are often tied to weakened bone.
The findings are notable because doctors have long debated whether rapid weight loss from GLP-1 drugs might harm bone health. The UCLA team said the large size of the study helped address a question that smaller studies could not answer with much confidence. Christopher Hamad said in a statement that “Fractures are relatively uncommon, so very large studies are needed to detect a meaningful difference,” adding that earlier research was often too small or not designed to examine fracture risk.
The authors stressed that the work was observational and cannot prove the drugs prevent fractures. Still, the results add to a growing body of research suggesting GLP-1 medicines may not increase fracture risk in people with type 2 diabetes, and may even be protective in some settings. Earlier studies published in JAMA Surgery also reported lower vertebral fracture risk among people with type 2 diabetes who used GLP-1 receptor agonists, while the JAMA Network Open paper suggested the association was driven mainly by a direct effect rather than by weight loss or improved blood sugar alone.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
